¥xÆW¤¤Âåºô¡B¥þ°ê³Ì¦h¤¤Âå®v§K¶OÂåÀø¿Ô¸ß¡B¤¤Âå¶E©Òºô¸ô±¾¸¹¤J¤f ¥xÆW¤¤Âåºô¡B¥þ°ê³Ì¦h¤¤Âå®v§K¶OÂåÀø¿Ô¸ß¡B¤¤Âå¶E©Òºô¸ô±¾¸¹¤J¤f
·j´M»¡©ú
65¤ÀÄÁ¦^ÂÐ
¡@§Ú¥h°ü²£¬ì±¾¸¹,Âå¥Í»¡¤p¡K

29¤ÀÄÁ¦^ÂÐ
¡@¤@¨Ç®ÄªG¸û¦n¸û±`¥Î©óÀY¾v¡K

33¤ÀÄÁ¦^ÂÐ
¡@1.½Ð°Ý³æ¤è(¦ó­º¯Q),1¤Ñ³Ì¡K

72¤ÀÄÁ¦^ÂÐ
¡@¤@¯ë¤H³£»¡³Ü¯ù¦ý¡A¦ý§Ú³Ü¡K

5¤ÀÄÁ¦^ÂÐ
¡@§Ú¥h¦~9¤ë¥ª¸}½ï¶´±a¼¹µõ¡K

53¤ÀÄÁ¦^ÂÐ
¡@Âå®v¦n¡G®a¤H¦]´Õ¶¡½L¥Y¥X¡K

榭G
A.¥Ñ±z¥H¤Wªº­z»¡ §Ú¥h°ü²£¬ì±¾¸¹,Âå¥Í»¡¤p²£¦å¬y¤£°®²b¥s§Ú¥h¤¤Âå¶R¡K
榭G
A.¥Ñ±z¥H¤Wªº­z»¡ §ä(¦³¸gÅç)¦X®æªº¤¤Âå®v¨Ó[¶Eªv]¡I ¬O¥i¥Hªv¡¥|¡K
榭G
1.¤@­Ó¦nªºªvÀø¤@©w­n§i¶D§A­ì¦]¡A¤~·|¥h°µ¡A«K¯¦´N¬O¦Yªº°ÝÃD¡AÅÖºû¯À¡K
榭G
1.¨S¦³²Óµß·P¬V¡A¶}§Ü¥Í¯À¬O¨S¦³·N¸qªº¡K
榭G
A.¥Ñ±z¥H¤Wªº­z»¡ @¤@¨Ç®ÄªG¸û¦n¸û±`¥Î©óÀY¾vÅܧó¦h¡BÀY¾vÅܧó²Êªº³æ¡K
  

±MÄæ¤å³¹
¤ÀÃþ ¯e¯f¯gª¬
¼ÐÃD ¯×ªÕ¨x
ÃöÁä¦r ¯×ªÕ¨x 
µoªí¤é´Á 2015-08-05
§@ªÌ ¾G®¶ÂE¤¤Âå®v 
ªA°È°|©Ò ¾G®¶ÂE¤¤Âå¶E©Ò 
¤å³¹¤º®e

 ³ü. «e¨¥

¯×ªÕ¨x¬O¦hºØ¯e¯f©M¯f¦]¤Þ°_ªº¨xŦ¯×ªÕ©Ê¯fÅÜ ¡A¤À¦³°sºë©Ê¯×ªÕ©Ê¨x¯f(alcoholic fatty liver disease)©M«D°sºë©Ê¯×ªÕ©Ê¨x¯f(nonalcoholic fatty liver disease)¡A¨ä¤¤¥H«D°sºë©Ê¯×ªÕ©Ê¨x¯f(NAFLD)¥e¦h¼Æ¡A¤SºÙ«D°sºë©Ê¯×ªÕ¨x¡A¬O¤@ºØµL¹L¶q¶¼°s¥v¡A¥H¨x¹ê½è²Ó­M¯×ªÕÅÜ©Ê©M¯×ªÕ¶J¿n¬°¯S¼xªºÁ{§É¯f²zºî¦XÃÒ¡C

1962¦~Thaler¦b¤åÄm¤¤¶}©l´y­z«D¶Ý°sªÌ¯×ªÕ¨x¡A1979¦~¦³¤åÄm¤À§O³ø§iªÎ­D¯g¡B¿}§¿¯f¬ÛÃö¯×ªÕ¨xµo¥Í¨xµw¤Æ¡A¨ä«áudwig(1980)©MSchaffner(1980)¬ÛÄ~´£¥X«D°sºë©Ê¯×ªÕ©Ê¨xª¢(nonalcoholic steatohepatitis¡ANASH)©M«D°sºë©Ê¯×ªÕ©Ê¨x¯f(nonalcoholic fatty liver disease¡ANAFLD)ªº·§©À¡C¥Ø«e»{¬°¯×ªÕ¨x¬O«ü¯×ªÕ©Ê¨x¯fªºÂ²ºÙ(1)¡C

«D°sºë©Ê¯×ªÕ¨x¬O¥xÆW±`¨£­±©Ê¨x¯f¤§¤@¡A¦b¦è¤èµo¹F°ê®a¡A¦¨¤H«D°sºë©Ê¯×ªÕ©Ê¨x¯f(NAFLD)±w¯f²v¤w¹F20~30%¡AÀHµÛªÀ·|¦Ñ¤Æ¤ÎªÎ­D©M¥NÁºî¦XÃÒªºNAFLD¤w³vº¥¼vÅT°·±d¡ANAFLD°£ª½±µ³q¹L«P¶i¨x¯f¶i®i¡A¾É­P¨x¥\¯à°IºÜ¡B¨x²Ó­MÀù¥~¡AÁÙ°Ñ»P2«¬¿}§¿¯f©M°Ê¯ßµ°ª¬µw¤Æªºµo¯f¡AÁöNAFLD¤£¼W¥[¨x¯f¬ÛÃö¦º¤`¡A¦ý¤ß¦åºÞ¬ÛÃö©M¥NÁ¬ÛÃö¸~½F¸û¥¿±`¤H©úÅã¼W¥[¡C

¥Ø«e»{¬°NAFLD¬O¤@ºØ»P¯Ø®q¯À©è§Ü(insulin resistance IR)©M¿ò¶Ç©ö·P¥NÁ¤ÏÀ³©Ê¨x·l¶Ë¡A¨ä¯f²z§ïÅÜ»P°sºë©Ê¨x¯f¬Û¦ü¡C­ìµo©ÊNAFLD¬O¥NÁºî¦XÃҲ֤ΨxŦªº¯f²zªí²{¡AÄòµo©ÊNALFD »PIR©M¥NÁµLÃö¡A¬O¥Ñ¦hºØÃĪ«¥H¤ÎC«¬¨xª¢¯f¬r·P¬V¡BÀç¾i¤£¨}¡B¨§ª¬®ÖÅÜ©Ê(Wilson disease)µ¥¯S©w¯e¯f¾É­P(2)¡C

¶L¡B¦èÂå¯f²z¾÷Âà

NALFD¬O¿ò¶Ç-Àô¹Ò-¥NÁ¤ÏÀ³¬ÛÃö©Ê¯e¯f¡AªÎ­D¡B2«¬¿}§¿¯f¡B°ª¯×¦å¯gµ¥³æ¿W©Î¦@¦Pºc¦¨NAFLDªº©ö·P¦]¯À¡C¬ÛÃö¬ã¨s¤ÀªR¡AÅé­«¦]¯À©M¸¡³ò/Áv³ò¤ñ­È¼W¥[¡B°ª¯×¦å¯g¡B°ª¦å¿}¡B°ª¦åÀ£¥H¤Î¦~ÄÖµ¥¦]¯À»P¯×ªÕ¨x±K¤ÁÃö«Y¡C¯f²z¾÷¨î¤À

(1) ªì¦¸¥´À»¥D­n¬°(Insulin resistance)IR¡AIR«P¨Ï¥~©P¯×ªÕ­°¸Ñ¼W¥[©M°ª¯Ø®q¯À¦å¯g¤Þ°_¨x²Ó­M¯×ªÕÀx¿n(a)¯×½è¹L¦h¯g¡G¯Ø®q¯À¥i§í¨î²É½uÅ骺B®ñ¤Æ¡A¨Ï²Ó­M¤º´åÂ÷¯×ªÕ»Ä¿@«×¼W°ª¡A¦Ó¨x²Ó­M¹ï¯×ªÕ»Äªº°ªÄá¤J¾É­P²É½uÅé®ñ¤Æ¶W¸ü¡A¥[­«¨x²Ó­M¤º¯×ªÕ»ÄªºÀx¿n¡C(b)°ª¯Ø®q¯À¦å¯g¡G¿}­°¸Ñ¼W¥[¡A¼W¥[¯×ªÕ»Äªº¦X¦¨¡A´î¤Ö¸ü¯×³J¥Õªº¦X¦¨¡A¨Ï¥Ìªo¤Gà­»W¿n¼W¥[¡C

(2) Kupffer²Ó­M»P²Ó­M¦]¤l ¨xŦKupffer²Ó­M¨ã¦³§]¾½¥\¯à¡B§]¶¼§@¥Î¤Î§K¬Ì½Õ¸`¥\¯à¡C²Ó­M¦]¤l¡B¤ÏÀ³©Ê®ñ¤Æ²£ª«©M¤@®ñ¤Æ´á¹ïKupffer²Ó­Mªº¥\¯à©M¤À¤Æ¦³­«­n§@¥Î¡Cµo¯f±¡ªp¤U¡AKupffer¹L«×¿E¬¡ÄÀ©ñ·»¸Ñ酶¡B®ñ¦Û¥Ñ°ò¥H¤ÎTNF-a¡BIL-b©MIL-1B¡B¦å¤pªO¬¡¤Æ¦]¤l¡B«e¦C¸¢¯Àµ¥²Ó­M¦]¤l©Mª¢©Ê¤¶½è¡A¾É­P©P³ò¨x²Ó­M·l¶Ë¡C

(3) ¯×½è¥NÁ¯¿¶Ã ¯×½è¥NÁ¯¿¶Ãªº±wªÌ¬ù50%¦ñ¦³¯×ªÕ¨x¡CÄY­«°ª¥Ìªo¤Tà­¦å¯g©M²V©M©Ê°ª¯×¦å¯g±wªÌ¯×ªÕ¨xµo¯f²v¸û¥¿±`¤H°ª5-6­¿¨xŦÄá¨ú´åÂ÷¯×ªÕ»Ä«á¨Ï¤§ÂàÅܦ¨¥Ìªo¤Tà­(TG)¡A¥Ìªo¤Tà­¦b»P¯S²§ªº¸ü¯×³J¥Õµ²¦X¥Í¦¨·¥§C±K«×¯×³J¥Õ¡C

(4) ®ñÀ³¿E»P¯×½è¹L®ñ¤Æ ¥Ñ©ó«P®ñ¤Æª«¼W¦h©M§Ü®ñ¤Æª«´î¤Öªº®ñÀ³¿E¡A®ñÀ³¿E¦b¯×ªÕ»W¿nªº¨xŦ¤¤¼W±j¡A¤ÏÀ³©Ê®ñ¤Æ²£ª«ÀHNAFLD¥[­«¦Ó¼W¦h¡CTNF-a²Ä¤G¦¸¥´À»¬°¤ÏÀ³©Ê®ñ¤Æ¥NÁ²£ª«¼W¦h¡A¾É­P¯×½è¹L®ñ¤Æ¦ñ²Ó­M¦]¤l¡B²É½uÅé¸Ñ°¸³J¥Õ(TNF-aªº½Õ¸`°ò¦])¥H¤Î½¤¨üÅé°tÅé³Q»¤¾É¬¡¤Æ¡A¶i¦Ó¤Þ°_¯×ªÕÅܪº¨x²Ó­Mµo¥Í®ð²y¼ËÅÜ©MÃa¦º©Êª¢¯g(¯×ªÕ©Ê¨xª¢¡A²Ä¤G¨B) ¡F¨xŦª¢¯g«ùÄò¦s¦b«h¤£¥iÁקK¦a¾É­P¨x¬Pª¬²Ó­M¬¡¤Æ©M¼W´Þ¡A±q¦Ó±Ò°Ê¨xŦ¿n­È±o­×¤ÏÀ³(¨xÅÖºû¤Æ¡A²Ä¤T¨B) ¡F¦ñÀH©ó¶i®i©ÊÅÖºû¤Æªº¨xŦ·L´`Àô»Ùê©ÒÄ~µoªº¯Ê¦å©ÊÃa¦º¾É­P¨x¤p¸­µ²ºc§ï«Ø¡A¦Ó»¤µo¨xµw¤Æ(²Ä¥|¨B) (3)¡C

©Ò¥H«D°sºë©Ê¯×ªÕ¨x¥D­n¤À¤T¯f²z¬q¡A§Y³æ¯Â©Ê¯×ªÕ¨x¡B¯×ªÕ©Ê¨xª¢©M¯×ªÕ©Ê¨xµw¤Æ¡C¨x²Ó­M¯×ªÕÅܩʱ`Äjº©²Ö¤Î¾ã­Ó¨xŦ¡A¨Ì¾Ú¨xŦ²Ö¤Î½d³ò±N¯×ªÕ¨x¤À»´¡B¤¤¡B­«3«¬¡C


°Ñ¡B¤¤Â媺¯f¦]¯f¾÷

®Ú¾Ú¯f¦]¤ÎÁ{§Éªí²{Äݤ¤Âå¿n»E¡B¯Ùµh¡B¨xµÛµ¥½dÃ¥¡C¯f¦]¬°¶¼­¹¤£¸`¡A¹L­¹ªÎ¥Ì«p¨ý¡A¤[§¤¤Ö°Ê¡Bºë¯«À£¤O¡B¹L«×ªÎ­D¡B±¡§Ó¤£µÎ¡B·P¨üÀã¼öµ¥¡C

¯f¾÷¯SÂI¬°¥»µê¼Ð¹ê¡A¥»µê¬°µÊ®ðµê®z¡A¨xµÇÁ«·l¡F¼Ð¹ê¬°·ðÀ㤺ĭ¡A®ðº¢¦å·ï¡C¯f¦ì¯A¤Î¨x¡BµÊ¡BµÇ¤TŦ¾¹¡C¥»¯f¦b¨x¡Aµo©óµÊ¡A¤Î©óµÇ¡C

¸v¡B¦èÂåÁ{§É¶EÂ_

Á{§É©ú½T¶EÂ_»Ý²Å¦X¤U3¶µ±ø¥ó¡G

(1) µL¶¼°s¥v©Î¶¼°s«h¦X¤A¾J¶q¤p©ó¨C©P140¤½§J(¤k©Ê<70¤½§J) ¡F(2)±Æ°£¯f¬r©Ê¨xª¢¡BÃĪ«©Ê¨x¯f¡B¥þ­G¸z¥~Àç¾i¡B¨x¨§ª¬®ÖÅÜ©Ê¡B¦Û¨­§K¬Ì©Ê¨x¯fµ¥¥i¾É­P¯×ªÕ¨xªº¯S©w¯e¯f¡F(3)¨x¬¡Åé²Õ´¾Ç§ïÅܲŦX¯×ªÕ©Ê¨x¯f¯f²z¾Ç¶EÂ_¼Ð·Ç¡C

ų©ó¨x²Õ´¾Ç¶EÂ_Ãø¥HÀò±o¡ADAFLD©w¸q¬°(1)¨xŦ¼v¹³¾Ç²Å¦XÄjº©©Ê¯×ªÕ¨xªº¶EÂ_¼Ð·Ç¥BµL¨ä¥L­ì¦]¥i¨Ñ¸ÑÄÀ¡F©M¡A©Î(2)¦³¥NÁºî¦XÃÒ¬ÛÃö²Õ¤Àªº±wªÌ¥X²{¤£©ú­ì¦]ªº¦å²MALT©M(©Î)AST¡BGGT«ùÄò¼W°ª¥b¦~¥H¤W¡C´îªÎ©M§ïµ½¯Ø®q¯À©è§Ü«á¡A²§±`酶©M¼v¹³¾Ç¯×ªÕ¨x§ïµ½¬Æ¦Ü«ì´_¥¿±`ªÌ¥i©ú½TNAFLDªº¶EÂ_¡C

¨Ì¾Ú¹ê¥Î¤º¬ì¾Ç¶EÂ_¼Ð·Ç¨ã³Æ²Ä1~5¶µ§ò¦a6©Î²Ä7¶µ¥ô¤@¶µªÌ§Y¥i¶EÂ_¬°NAFLD¡G(1)¦³©ö±w¦]¯À¦pªÎ­D¡B2«¬¿}§¿¯f¡C°ª¯×¦å¯gµ¥¡F(2)µL¶¼°s¥v©Î¶¼°s­õ©M°sºë¶q¨C©P<40¤½§J¡F(3)±Æ°£¯f¬r©Ê¨xª¢¡BÃĪ«©Ê¨x¯f¡BWilson¯f¡B¥þ­G¸z¥~Àç¾i©M¦Û¨­§K¬Ì©Ê¨x¯fµ¥¡F(4)°£­ìµo¯fÁ{§Éªí²{¥~¡A¥i¥X²{¥F¤O¡B¨x°ÏÁôµhµ¥¯gª¬¡A¥i¦ñ¨xµÊ¸~¤j¡F(5)¦å²MÂà¦w酶¥i¤É°ª¡A¨Ã¥HALT¬°¥D¡A¥i¦ñ¦³GGT¡BÅK³J¥Õ©M§¿»Ä¼W°ª¡F(6)¨x²Õ´¾Ç¦³¨å«¬ÅÀªí²{¡F(7)¦³¼v¹³¾Ç¶EÂ_¨Ì¾Ú¡C

¥Í¤ÆÀËÅç³Ì±`¨£¬°¦å²MÂà¦w酶AST/ALT¤W¤É2~5­¿¥iªí²{¬°AST/ALT>1¡A¦ý¤£·|>2¡A»P¯×ªÕ©Ê¨xª¢©MÅÖºû¤Æµ{«×¤§¶¡¤£¦s¦b¬ÛÃö«Y¡C<50%ªºNAFLDÆP©ÊÁC»Ä酶(ALP) ¡Br-¨¦®ò酰Âà酞酶(GGT)¥i¤É°ª2~3­¿¡C

Á{§É¤À«¬

a³æ¯Â©Ê¯×ªÕ¨x

¨ã³Æ¤U¦C²Ä1~2¶µ©M²Ä3¶µ©Î²Ä4¶µ¥ô¤@¶µ§Y¥i¶EÂ_¡G(1)¨ã³ÆÁ{§É¶EÂ_¼Ð·Ç1~4¶µ¡A(2)¨x¥\¯àÀˬd°ò¥»¥¿±`¡A(3)¼v¹³¾Çªí²{²Å¦X»´¡B¤¤«×¯×ªÕ¨x¡A(4)¨x²Õ´¾Çªí²{²Å¦X³æ¯Â©Ê¯×ªÕ¨x¡AµL©úÅã¨x¤ºª¢¯g©MÅÖºû¤Æ(4)¡C

b«D°sºë©Ê¯×ªÕ©Ê¨xª¢

¨ã³Æ¤U¦C²Ä1~2¶µ©M²Ä3©Î²Ä4¶µ¥ô¤@¶µ§Y¥i¶EÂ_¡G(1)¨ã³Æ¶EÂ_¼Ð·Ç1~4¶µ¡A(2)¦å²MALT©M(©Î)GGT°ª©ó¥¿±`­È¤W­­ªº1~5­¿¡A«ùÄò®É¶¡¤j©ó¥|©P¡A(3)¦³¼v¹³¾Ç¶EÂ_®Ú¾Ú¡A(4)¨x²Õ´¾Ç¶EÂ_¥¿½T¡C

C¯×ªÕ©ÊÅÖºû¤Æ©Î¨xµw¤Æ

¨ã³Æ¤U¦C²Ä1~2¶µ©M²Ä3¶µ©Î²Ä4¶µ¥ô¤@¶µ§Y¥i¶EÂ_¡G(1)¨ã³ÆÁ{§É¶EÂ_¼Ð·Ç1~4¶µ¡A(2)¨x¥\¯à©M¦å²MÅÖºû¤Æ¼Ð»x¥i¥¿±`©Î²§±`¡A(3)¼v¹³¾ÇÅã¥Ü¯×ªÕ¨x¦ñ¨xÅÖºû¤Æ©Î¨xµw¤Æ¡A(4)¨x²Õ´¾Ç¶EÂ_ÃÒ¹ê¡C

¥î¡B¦èÂåªvÀø

NAFLD¥i¾É­P¨x¯f¬ÛÃö´Ý¯e©M¦º¤`¡AÁÙ»P°Ê¯ßµ°ª¬µw¤Æ©Ê¤ß¸£¦åºÞªº°ªµo²v¬ÛÃö«Y¡A¦]¦¹NAFLDªvÀøªº­º­n¥Ø¼Ð¬O±±¨î¦U¶µ¥NÁ¯¿¶Ã¡A¨¾ªv¿}§¿¯f©M°Ê¯ßµ°ª¬µw¤Æ©Ê¤ßŦ¦åºÞ¯e¯f¡A¨ä¦¸¬°°fÂà¨x²Ó­M¯×ªÕ¯fÅÜ¡A¨¾ªv¨xµw¤Æ©M¨x¸~½Fµo¥Í¡CªvÀø­ì«h¬°°·±d½Ã±Ð¡A§ïÅܤ£¨}¥Í¬¡²ß©Ê¡A±±¨îÅé­«¡AÁY¤p¸y³ò¡A±±¨î¦å¿}¡A½Õ¾ã¦å¯×¡A­°§C¦åÀ£¡FÁקK¥[­«¨x·l¶Ë¦]¯À¡BÃĪ«¨¾ªv©M¨xÅÖºû¤Æ¡B¥½´Á¦Ò¼{¨x²¾´Ó¡C

(1) ¶¼­¹©M¹B°Ê

§C¿}§C¯×ªº¥­¿Å¿¯­¹¡A´î¤Ö§t¿}¶¼®Æ¥H¤Î¹¡©M¯×ªÕ¡B¤Ï¦¡¯×ªÕÄá¤J¡A¾A·í¼W¥[¿¯­¹ÅÖºû§t¶q¡F¤¤µ¥¶q¦³®ñ¹B°Ê¡A¨C©P4¦¸¥H¤W¡A²Ö­pÁëÁå®É¶¡¦Ü¤Ö150¤ÀÄÁ¡C³q¹L§ïÅܥͬ¡¤è¦¡´îªÎ¥iªv¡IR¬ÛÃöªºNAFLD¡A¨Ã¨Ï¨xÂà¦w酶¥¿±`¡A¨x¯×ªÕµ{«×´î»´¡C

(2) ÃĪ«ªvÀø

1¡B ­°¦å¯×ÃĪ«

­°¤T»Äªo¯×¬°¥DClofibrateÃþ¡B¥H­°Áx©T¾JÃþ¬°¥DHMG—CoAÁÙ­ì酶§í¨î¾¯¡A¦ý¦Ü¤µ©|µL­°¯×ÃĪ«¹ï¨x¤º¯×ªÕ¨I¿n¦³´î»´§@¥ÎªºÃÒ¾Ú¡A¬Æ¦Ü³¡¤ÀÃĪ«¨Ï¯×½è¨I¿n©ó¨x¡A¥»¨­¹ï¨x¦³¬r©Ê¡C¬G¤£¦ñ°ª¯×¦å¯gªºNAFLD±wªÌ­ì«h¤£¥Î­°¦å¯×ÃÄ¡C

2¡B Å@¨x¥h¯×ÃÄ

»ÝÁC¯×¨ã¦³½¤Ã­©w§@¥Î¡A¦P®É¹ïÅ餺¯×ªÕªº§l¦¬¡BÂà¹B©M¦h¬[¤£¹¡©M¯×ªÕ»ÄªºÀx¦s°_­«­n§@¥Î¡C

3¡B ºµ¥h¾iÁx»Ä(Ursodeoxycholic acid)

¨ã¦³¼W¥[Áx¥Ä¤¤¯×½èªº¤Àªc¡B½¤Ã­©w¡B²Ó­M«OÅ@¡B§Ü­ä¤`¤Î§K¬Ì½Õ¸`µ¥§@¥Î¡C

4¡B §Ü®ñ¤Æ¾¯

ºû¥Í¯ÀE¡Bºû¥Í¯ÀA¡BSilymarin(©úÅã«OÅ@©Mí©w¨x²Ó­M½¤ªº§@¥Î¡A¹ï¦UºØÃþ«¬¨x·l¶Ë¨ã¦³¤£¦Pµ{«×ªº«OÅ@©MªvÀø§@¥Î(5)¡C

(3) ¥~¬ì¤â³N

1¡B ´îªÎ¤â³N

­G¸z¹D¤â³N©M§½³¡¥h¯×³N¡C

2¡B ¨x²¾´Ó

NAFLDµo®i­P±ß´Á¨xµw¤Æ¡B¨x¥\¯à°IºÜ¡BªùÀR¯ß°ªÀ£¤Î¨ä¨Öµo¯g©M¨xÀù¥i¬°¯e±wªÌ¥Í©R¡A¦¹®É¨x²¾´Ó¬O·m±Ï¥Í©Rªº°ß¤@¿ï¾Ü¡C

³°¡B¤¤Âå¿ëÃÒ»PªvÀø

°Ñ¦Ò2006¦~¤¤µØ¤¤ÂåÃľǷ|µÊ­G¯f¤À·|½sµÛ¡m¤¤Âå®ø¤Æ¯f¶EÀø«ü«n¡n(6)©M¤¤¦èÂåµ²¦X¨xŦ¯f¾Ç(7)

(¤@) ¨xÆ{®ðº¢ÃÒ

¥DÃÒ¡G¨x°Ï¤£¾A¡A¨â脇µÈº¡¯kµh¡A¯Ý´eµ½¤Ó®§¡A±¡§Ó§íÆ{¡C

¦¸ÃÒ¡G¯Ç¤Ö¡A¾¼®ð¤£µÎ¡A¤j«K¤£¡A¸g¦æ¤£ºZ¡B¨Å©ÐµÈµh¡A¦Þ½è¬õ­LÁ¡¥Õ¡A¯ß©¶·Æ©Î©¶²Ó¡C

ªvªk¡G²¨¨x¸ÑÆ{¡A²z®ð©M­G

¤èÃÄ¡G®ã­J²¨¨x´²¥[´î¡A脇µh­«ªÌ¥[«C¥Ö¡BÆ{ª÷¡A®ðÆ{¤é¤[¤Æ¼ö¥[¨d¤¦¥Ö¡B±÷¤l¡A¶Ë³±¥[¥Í¦a¶À¡C

(¤G) ¨xÆ{µÊµêÃÒ

¥DÃÒ¡G¯Ý脇µÈ´e¡A­Â«å¥F¤O¡A¸¡µh¸¡Âm¡A±¡§Ó¤£µÎ

¦¸ÃÒ¡G­¹¼¤®t¡A¹Ã§c¤£µÎ¡AµÈº¡¤£¾A¡A®É±ý¤Ó®§¡A¦Þ½è²H¬õ­a¥Õ©ÎÁ¡¥Õ¡A¯ß©¶²Ó

ªvªk¡G²¨¨x°·µÊ¡A¦æº¢´²µ²

¤èÃÄ¡G³p»»´²¥[´î¡A¸¡µÈ¥[«p¦µ¡B»a¥º¡B¬â¤¯¡C

(¤T) ·ðÀ㤺ªýÃÒ

¥DÃÒ¡G§ÎÅéªÎ­D¡A脇¦ØµÈ´e¤£¾A¡A©P¨­§x­«¡A¤j«KÂHº¢¤£²n¡A

¦¸ÃÒ¡GµÈº¡¤£¾A¡A­Â«åµL¤O¡A­¹¼¤¤£®¶ ¡AÀY­«¦p»q¡Bäú¤ß±ý¦R¡A¦Þ½è²H­a¥ÕÃ侦²ª¡A¯ßÀá·Æ¡C

ªvªk¡G°·µÊÀêÀã¡A¤Æ·ð§QÀã

¤èÃÄ¡G¥­­G´²©M¤G³¯´ö¥[´î¡A¸¡µÈº¡¥[¤j¸¡¥Ö¡BµÜµè¤l¡A®ø¤Æ¤£¨}¡A¤j«KÞFÁ¡¥[¯«¦±¡BµJ¤sÝÓ¡BÂû¤ºª÷¡B¥Õ«ó¨§¡A¦ñÀã¼ö¥[¤Ö¶q¶ÀÍÁ¡B¶À³s¡C

(¥|) Àã¼öÄ­µ²ÃÒ

¥DÃÒ¡G¨­ÅéªÎ­D¡A©P¨­§x­«¡A×E¸¡µÈº¡¤£µÎ¡A¤j«KÂH¿°¤£²n

¦¸ÃÒ¡G¨­¥Øµo¶À¡A¤p«K¶À¨ª¡A¤f¤¤ÂH¿°¡B¤f­W¡A¦Þ½è¬õ­a¶À¿°¡A¯ß©¶·Æ©Îµy¼Æ¡C

ªvªk¡G²M¼ö§QÀã

¤èÃÄ¡G¯ô³¯»U´ö¥[´î¡A¸¡µÈ´eªÌ¥[ÏL¹ê¡B¤ì­»¡B³¯¥Ö¡B«p¦µµ¥¡A¥k脇¦Øµh¬ÆªÌ¥[Æ{ª÷¡B¤t·¯¤l¡B¥Õ¨¢¡B¥È­J¡A¸¡¤ô©M¤­­d´²¥[´î¡Aäú¤ß¹Ã¦R¥[¶À³s¡B¦Ë¯ø¡B¬â¤¯¡C

(¤­) ·ð·ï¤¬µ²ÃÒ

¥DÃÒ¡G§ÎÅéªÎ­D¡A­±¦â±â·t¡A脇¤Uµl¶ô¡A¯Ý脇¨ëµh©Î¶wµh

¦¸ÃÒ¡G¯Ý×Eµlº¡¡A«£¦R·ð²C¡A¯Ç§b¡A¥|ªÏ¨I­«¡A¦Þ½èÅf¬õ¦³·ï´³Ã䦳¾¦²ª­a¿°¡A¯ß©¶·Æ©Î©¶Àß¡C

ªvªk¡G¬¡¦å¤Æ·ï¡AÒç·ð´²µ²

¤èÃÄ¡G»J¤U³v·ï´ö©M¤G³¯´ö¥[´î¡AÅ髬ªÎ­D¦³°ª¦å¯×¯gªÌ¥[²ü¸­¡B¥Í¤sÝÓ¡B¨M©ú¤l¡A¤j«K¤£ºZ¥[¥Í¤j¶À¡A¦å·ï©úÅã¥[¬õªá¡B¤¦°Ñ¡C(8)

(¬m)µ²½×

«D°sºë©Ê¯×ªÕ©Ê¨x¯f¡AÀHµÛªÎ­D©M¥NÁºî¦X¯gªº³vº¥¼W¦h¡Aªñ20¦~¨ÓNAFLD¼Wªø¨³³t¥B§CÄÖ¤ÆÁͶաA¤w¦¨¬°¥þ²y­«­n¤½¦@°·±d°ÝÃD¤§¡A¥ç¬O¥xÆW·U¨Ó·U­«­n±`¨£ºC©Ê¨x¯f¡C¥Ñ©ó¦h¼Æ±wªÌªø´Áí©w¦ÓµL©úÅã¯gª¬¡A±`³Q©¿µø¡A¤×¨ä¦Ñ¦~Áô·½©Ê¨xµw¤Æ±wªÌ¯f¥v¦³¯×ªÕ¨x¡BªÎ­D¯g¡B2«¬¿}§¿¯f¡A­ÓÅéªvÀø¤Î¯f¦]ªvÀø¥~¡A¤j¦h¼Æªº¦èÃÄ­°¦å¯×ÃĪ«¡A¨ã¦³«P¶i¦å²G¤¤ªº¯×½è¶i¤J¨xŦ¥NÁ±ƪn§@¥Î¡A·¥©ö¾É­P¨x·l¶Ë©M¯×ªÕ¨x¥[¼@¡F¤¤¦èÂåµ²¦XªvÀøªº¤¬¸É§@¥Î¡A¤w³Q¤½»{¦³¬Û­¼®ÄªG¡C¦]¦¹°w¹ï¥¼¨Ó·s¯e¯f¡A¤¤Âå°£­n¨Ì¯fªº¿ëÃҽתv¥~¡A¤]À³¹ï¦èÂå¯e¯fªº¯f²z¾÷Â঳©Ò»{ÃѤF¸Ñ¡A¤~¯à¹ï¯e¯f§ó²`¤J¡A¥ÎÃÄ»º¤è§óºë½T¡A¤¤ÂåÃĤè¯à¡i¥j¤µ±µ­y¡A¤¤¦è¥æ¿Ä¡j¡A¥ÃÄòµo´­©ó¥@¬É¡C

(®Ã)°Ñ¦Ò¸ê®Æ

(1)Cao HX¡AFan JG Fatty liver disease¡GJ Dig Dis 2011¡A12(1) ¡G1-2

(2)EcKel RH Grundy SM¡AZimmet PZ¡AThe metabolic syndrome LANCET¡A2005¡A365(9468) ¡G1415-1428

(3)Nugent C Younossi ZM. Evaluation and management of obesity-relate nonalcoholic fatty liver disease Gastroenterology Hepatol¡A2007¡A4(8):432-441

(4)³¯ø¯¯] ªLªG¬° ¥D½s ¹ê¥Î¤º¬ì¾Ç ¤H¥Á½Ã¥Í¥Xª©ªÀ 2009¦~9¤ë 13ª© ¡G2102-2104

(5)¿ð®a±Ó¥D½s ¹ê¥Î¦å¯×¾Ç ¤H¥Á½Ã¥Í¥Xª©ªÀ 2010¦~10¤ë (!)¡G232-238

(6)Caldwell SH¡AOelsner¡ALezzni JC Crytogenic cirrhosis¡GClinical characterization and risk factors for underlying disease¡AHepatology¡A1999¡A29¡G664-669

(7)©PºÖ¥Í¥D½s ¨x¯f¤¤ÂåÁ{ÃÒ¦®­n ¼sªF¬ì§Þ¥Xª©ªÀ 2010¦~10¤ë (1)¡G131-148

(8)ÃQÞ³ ­ðÆAµÓ ¥D½s ®ø¤Æ¨t²Î¦èÂåÃøªv¯fºØ ¤¤¦èÂåµ²¦X¶EÀø¤è²¤ ¤H¥Á½Ã¥Í¥Xª©ªÀ 2012¦~10¤ë (1) ¡G447-452

·PÁ ·PÁ¾G®¶ÂE¤¤Âå®v§ë½Z¥»ºô¯¸¡AÂà¸ü½Ð¨ú±o­ì§@ªÌ¦P·N¡C
ÂI¾\¼Æ 12867

   ¨ä¥¦¬ÛÃö¥DÃDªº¤å³¹¡G
   ¨ä¥¦ÁÙ¦³¬ÛÃö¥DÃDªº¤å³¹44½g




¡u¥»ºô©Ò´£¨Ñªº°·±d¿Ô¸ß¡AµLªk¨ú¥NÂå®v¤§·í­±¶EÂ_¡A¥çµLªk´£¨ÑÂåÀø¦æ¬°¡A­Y¹J¯e¯f¤´½Ð¾¨³t´NÂå¡v
¥»ºô¯¸´£¨Ñ°·±dª¾ÃѸê°T¡A¸T¤î¥ô¦óºô»Úºô¸ôªA°È·~ªÌÂà¿ýºô¯¸¸ê°T¤º®e

¢x

¢x
¢x
¢x
¢x
¢x
¢x
¢x
¡@Copyright © 5151½u¤W°·±d·ÓÅ@Áp·ù    ¡u¤u¬ã°|¤å¦rÂà»y­µ¸Õ¥ÎªA°È²£¥X¤§¦X¦¨»y­µ¡v¡@ªA°È«H½c: ¼g«Hµ¹§Ú­Ì¡@